文献速递肝病

海藻酸盐微囊化人肝细胞治疗儿童急性肝衰竭

Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children.
PubMed 文献 · J Hepatol · 2019-12-13

本研究在免疫健全大鼠中验证临床级人肝细胞微珠(HMB)安全性后,对8例等待肝移植的急性肝衰竭(ALF)患儿行腹腔内HMB移植。操作耐受良好无并发症,4例避免肝移植、3例成功桥接至肝移植,回收HMB结构完整且肝细胞有活力、功能保留。

要点

  • 儿童ALF中腹腔内HMB移植可行且安全,无操作相关并发症。
  • 8例中4例避免肝移植,3例成功桥接至肝移植。
  • 回收HMB结构完整、无宿主细胞黏附,肝细胞有活力且功能保留。

核心结论

  • HMB输注在儿童ALF中可行且安全。

研究设计与样本

  • 先在免疫健全健康大鼠中测试临床级人肝细胞微珠(HMB)与空微珠。
  • 随后对8例等待合适同种异体肝移植的ALF患儿行腹腔内HMB移植,监测操作并发症、宿主免疫反应及回收HMB的残余功能。

主要发现

  • 健康大鼠腹腔内HMB移植安全,保留合成与解毒功能且无需免疫抑制。
  • 8例患儿中4例新生儿血色病、2例病毒感染、2例输注时病因不明,中位年龄14.5天(范围1天至6岁)。
  • 操作耐受良好无并发症;4例避免肝移植,3例成功桥接至肝移植。
  • 输注后(肝移植时)回收的HMB结构完整、无宿主细胞黏附,含存活肝细胞且功能保留。

临床怎么用

  • 对等待肝移植的儿童ALF,HMB腹腔内移植可作为安全可行的桥接或支持手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver transplantation (LT) is the most effective treatment for patients with acute liver failure (ALF), but is limited by surgical risks and the need for life-long immunosuppression. Transplantation of microencapsulated human hepatocytes in alginate is an attractive option over whole liver replacement. The safety and efficacy of hepatocyte microbead transplantation have been shown in animal models. We report our experience of this therapy in children with ALF treated on a named-patient basis. METHODS: Clinical grade human hepatocyte microbeads (HMBs) and empty microbeads were tested in immunocompetent healthy rats. Subsequently, 8 children with ALF, who were awaiting a suitable allograft for LT, received intraperitoneal transplantation of HMBs. We monitored complications of the procedure, assessing the host immune response and residual function of the retrieved HMBs, either after spontaneous native liver regeneration or at the time of LT. RESULTS: Intraperitoneal transplantation of HMBs in healthy rats was safe and preserved synthetic and detoxification functions, without the need for immunosuppression. Subsequently, 8 children with ALF received HMBs (4 neonatal haemochromatosis, 2 viral infections and 2 children with unknown cause at time of infusion) at a median age of 14.5 days, range 1 day to 6 years. The procedure was well tolerated without complications. Of the 8 children, 4 avoided LT while 3 were successfully bridged to LT following the intervention. HMBs retrieved after infusions (at the time of LT) were structurally intact, free of host cell adherence and contained viable hepatocytes with preserved functions. CONCLUSION: The results demonstrate the feasibility and safety of an HMB infusion in children with ALF. LAY SUMMARY: Acute liver failure in children is a rare but devastating condition. Liver transplantation is the most effective treatment, but it has several important limitations. Liver cell (hepatocyte) transplantation is an attractive option, as many patients only require short-term liver support while their own liver recovers. Human hepatocytes encapsulated in alginate beads can perform the functions of the liver while alginate coating protects the cells from immune attack. Herein, we demonstrated that transplantation of these beads was safe and feasible in children with acute liver failure.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dhawan A, Chaijitraruch N, Fitzpatrick E, et al. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children. J Hepatol. 2019. PMID: 31843649. doi:10.1016/j.jhep.2019.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。